Toggle Main Menu Toggle Search

Open Access padlockePrints

Genome-Wide Association Study of Classical Hodgkin Lymphoma and Epstein-Barr Virus Status-Defined Subgroups

Lookup NU author(s): Professor Peter Thomson

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Accumulating evidence suggests that risk factors for classical Hodgkin lymphoma (cHL) differ by tumor Epstein-Barr virus (EBV) status. This potential etiological heterogeneity is not recognized in current disease classification. We conducted a genome-wide association study of 1200 cHL patients and 6417 control subjects, with validation in an independent replication series, to identify common genetic variants associated with total cHL and subtypes defined by tumor EBV status. Multiple logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) assuming a log-additive genetic model for the variants. All statistical tests were two-sided. Two novel loci associated with total cHL irrespective of EBV status were identified in the major histocompatibility complex region; one resides adjacent to MICB (rs2248462: OR = 0.61, 95% CI = 0.53 to 0.69, P = 1.3 x 10(-13)) and the other at HLA-DRA (rs2395185: OR = 0.56, 95% CI = 0.50 to 0.62, P = 8.3 x 10(-25)) with both results confirmed in an independent replication series. Consistent with previous reports, associations were found between EBV-positive cHL and genetic variants within the class I region (rs2734986, HLA-A: OR = 2.45, 95% CI = 2.00 to 3.00, P = 1.2 x 10(-15); rs6904029, HCG9: OR = 0.46, 95% CI = 0.36 to 0.59, P = 5.5 x 10(-10)) and between EBV-negative cHL and rs6903608 within the class II region (rs6903608, HLA-DRA: OR = 2.08, 95% CI = 1.84 to 2.35, P = 6.1 x 10(-31)). The association between rs6903608 and EBV-negative cHL was confined to the nodular sclerosis histological subtype. Evidence for an association between EBV-negative cHL and rs20541 (5q31, IL13: OR = 1.53, 95% CI = 1.32 to 1.76, P = 5.4 x 10(-9)), a variant previously linked to psoriasis and asthma, was observed; however, the evidence for replication was less clear. Notably, one additional psoriasis-associated variant, rs27524 (5q15, ERAP1), showed evidence of an association with cHL in the genome-wide association study (OR = 1.21, 95% CI = 1.10 to 1.33, P = 1.5 x 10(-4)) and replication series (P = .03). Overall, these results provide strong evidence that EBV status is an etiologically important classification of cHL and also suggest that some components of the pathological process are common to both EBV-positive and EBV-negative patients.


Publication metadata

Author(s): Urayama KY, Jarrett RF, Hjalgrim H, Diepstra A, Kamatani Y, Chabrier A, Gaborieau V, Boland A, Nieters A, Becker N, Foretova L, Benavente Y, Maynadie M, Staines A, Shield L, Lake A, Montgomery D, Taylor M, Smedby KE, Amini RM, Adami HO, Glimelius B, Feenstra B, Nolte IM, Visser L, van Imhoff GW, Lightfoot T, Cocco P, Kiemeney L, Vermeulen SH, Holcatova I, Vatten L, Macfarlane GJ, Thomson P, Conway DI, Benhamou S, Agudo A, Healy CM, Overvad K, Tjonneland A, Melin B, Canzian F, Khaw KT, Travis RC, Peeters PHM, Gonzalez CA, Quiros JR, Sanchez MJ, Huerta JM, Ardanaz E, Dorronsoro M, Clavel-Chapelon F, Bueno-de-Mesquita HB, Riboli E, Roman E, Boffetta P, de Sanjose S, Zelenika D, Melbye M, van den Berg A, Lathrop M, Brennan P, McKay JD

Publication type: Article

Publication status: Published

Journal: Journal of the National Cancer Institute

Year: 2012

Volume: 104

Issue: 3

Pages: 240-253

Print publication date: 27/01/2012

ISSN (print): 0027-8874

ISSN (electronic): 1460-2105

Publisher: Oxford University Press

URL: http://dx.doi.org/10.1093/jnci/djr516

DOI: 10.1093/jnci/djr516


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Health Research Board, Ireland
Kay Kendall Leukaemia Fund
L'Institut National du Cancer, France
Plan Danmark
Compagnia di San Paolo - Programma Oncologia
05045Leukaemia Research Fund
06/02/0073Spanish Ministry of Health
00/73Leukaemia & Lymphoma Research
06001Leukaemia & Lymphoma Research
16-02-DNordic Cancer Union
08031Leukaemia Research Fund
41-08Danish Cancer Research Foundation
1999-008471La Fondation de France
2009/1084Swedish Cancer Society
920-03-136Netherlands Organisation of Scientific Research (NWO-MW)
DJCLS_R04/08German Jose Carreras Leukemia Foundation
DP 08-155Danish Cancer Society
FIS 08-1555Spanish Ministry of Health
FP6-2003-FOOD-2-BEuropean Commission
MZ0 MOU2005Ministry of Health of the Czech Republic
QLK4-CT-2000-00422European Commission
R01 CA69269United States National Institutes of Health
R19-A2364Lundbeck Foundation
RUG 2000-2315Dutch Cancer Society (KWF)
StSch4261Federal Office for Radiation Protection
StSch4420Federal Office for Radiation Protection
RUG 2010-4860Dutch Cancer Society (KWF)

Share